NASDAQ:OTIC - Otonomy Stock Price, Price Target & More

Otonomy trades on the NASDAQ under the ticker symbol "OTIC."

Otonomy Inc (NASDAQ:OTIC) issued its quarterly earnings data on Thursday, March, 8th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating the Zacks' consensus estimate of ($0.67) by $0.05. The biopharmaceutical company had revenue of $0.27 million for the quarter, compared to analysts' expectations of $0.46 million. Otonomy had a negative net margin of 6,316.88% and a negative return on equity of 58.60%. Otonomy's revenue was down 1.1% on a year-over-year basis. View Otonomy's Earnings History.

4 Wall Street analysts have issued 1 year price targets for Otonomy's stock. Their forecasts range from $8.00 to $15.00. On average, they anticipate Otonomy's stock price to reach $10.00 in the next year. View Analyst Ratings for Otonomy.

Some companies that are related to Otonomy include TIGENIX/S (TIG), Achaogen (AKAO), Insys Therapeutics (INSY), Evelo Biosciences (EVLO), Cara Therapeutics (CARA), Mersana Therapeutics (MRSN), Achillion Pharmaceuticals (ACHN), Aurinia Pharmaceuticals (AUPH), Obseva (OBSV), ZEALAND PHARMA/S (ZEAL), Clementia Pharmaceuticals (CMTA), Cytokinetics (CYTK), Concert Pharmaceuticals (CNCE), Zymeworks (ZYME) and ProMetic Life Sciences (PFSCF).

News coverage about OTIC stock has trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Otonomy earned a media sentiment score of 0.12 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 45.66 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Otonomy's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.77%), Dimensional Fund Advisors LP (3.68%), JPMorgan Chase & Co. (0.87%), Millennium Management LLC (0.38%), Sofinnova Ventures Inc (0.32%) and A.R.T. Advisors LLC (0.21%). Company insiders that own Otonomy stock include Carl Lebel and Eric J Loumeau. View Institutional Ownership Trends for Otonomy.

OTIC stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and A.R.T. Advisors LLC. View Insider Buying and Selling for Otonomy.

OTIC stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Dimensional Fund Advisors LP, Sofinnova Ventures Inc, Trexquant Investment LP and BlackRock Inc.. View Insider Buying and Selling for Otonomy.

Shares of OTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of OTIC stock can currently be purchased for approximately $4.45.

Otonomy has a market capitalization of $134.54 million and generates $1.24 million in revenue each year. The biopharmaceutical company earns $-90,130,000.00 in net income (profit) each year or ($2.97) on an earnings per share basis. Otonomy employs 53 workers across the globe.

Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 619-323-2200 or via email at [email protected]